Monsanto Co. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co.

MTC 2.490

+1.2%

Nov 26 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Professor Dotcomm who wrote (2001)	5/5/1999 9:07:00 AM
From: jopawa	Read Replies (1) of 2539

Monsanto (NYSE:MTC - news) gained $2.12 to $47.58 after the agricultural-biotechnology company announced that it is doesn't expect to spin off its Searle drugmaking unit. The decision prompted several analysts to upgrade the shares including Donaldson Lufkin & Jenrette, which has a twelve-month price target of $60 per share, and Salomon Smith Barney, which has a $55 per share price target. Both cited Searle's contributions to earnings growth for the recommendations.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next